Welcome to our dedicated page for LadRx news (Ticker: LADX), a resource for investors and traders seeking the latest updates and insights on LadRx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LadRx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LadRx's position in the market.
LadRx (OTCQB: LADX) announces plans to pursue FDA marketing approval for aldoxorubicin through the 505(b)(2) pathway for treating soft tissue sarcoma. This approach could accelerate market entry without requiring additional human clinical studies, as it leverages existing data from doxorubicin. The company regained control of aldoxorubicin following the termination of its NantCell license agreement in June 2024.
The company plans to request a pre-NDA meeting with FDA mid-2025, subject to additional funding. Aldoxorubicin delivers 3.5-4 times greater doses of doxorubicin without significant heart muscle effects, even at doses exceeding 5,000 mg/m2. LadRx has received a $1 million milestone payment related to arimoclomol and is evaluating various funding pathways.
LadRx (OTCQB: LADX) and ImmunityBio have agreed to mutually terminate the aldoxorubicin license, returning control of the drug to LadRx. This move follows LadRx's 2023 transfer of royalty and milestone rights of aldoxorubicin to XOMA for $5 million upfront, potentially up to $7 million more in milestones. XOMA has consented to the termination and will receive a low-single-digit synthetic royalty on aldoxorubicin and a mid-single-digit percentage from future out-license agreements. Aldoxorubicin, part of LadRx's LADR-based drug program, has shown promise in clinical trials with lower cardiotoxicity compared to doxorubicin. LadRx plans to review aldoxorubicin's data for further clinical development and expects to file an IND for another drug, LADR-7, by late 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
LadRx Corporation (OTCQB: LADX) has been granted a patent by the USPTO for its maytansinoid-based drug delivery systems. This innovation aims to enhance the delivery of chemotherapeutic agents, allowing for nearly 10 times the dosing of traditional methods. The company's lead drug candidate, Aldoxorubicin, is out-licensed to Immunity Bio, Inc., currently undergoing clinical trials for pancreatic cancer. LadRx's next-generation drugs, LADR7-10, are poised to enter IND-enabling activities and could be ready for Phase 1 trials within 18 months. The patent solidifies LadRx's IP portfolio, supporting its cancer treatment initiatives.
LadRx Corporation (OTCQB: LADX) has initiated a strategic review to maximize shareholder value, exploring options like mergers, financing, and potential stock splits for NASDAQ up-listing. CEO Stephen Snowdy emphasized the potential of Arimoclomol and Aldoxorubicin, along with next-generation oncology drugs. The rights to Arimoclomol were sold to Zevra Therapeutics, which may bring up to $120M in milestones if successful in FDA submissions. Aldoxorubicin could generate up to $343M through Immunity Bio, which is advancing clinical trials. The Company has engaged Roth Capital Partners for advisory support during this review process.
LadRx Corporation (OTCQB: LADX) provides a quarterly update for Q3 2022, highlighting its biopharmaceutical advancements, particularly in cancer therapeutics. The company focuses on its LADR technology, enabling targeted chemotherapeutic delivery. Key developments include the next-gen LADR drug candidates LADR7-10 and the progress of Aldoxorubicin, now in clinical trials under Immunity Bio (NASDAQ: IBRX). Financially, LadRx aims to extend its cash runway into mid-2023 while seeking additional funding amidst challenging market conditions.
LadRx Corporation (OTCQB: LADX) has announced a change in its OTCQB ticker symbol from CYTR to LADX, effective October 6, 2022. This decision aligns with the company's rebranding efforts, including its name change earlier this year. CEO Stephen Snowdy emphasized that the new symbol reflects the company's focus on its unique product platform, which includes the clinical drug Aldoxorubicin and four pre-clinical cancer therapeutics. Shareholders do not need to take any action, and the company's corporate structure will remain unchanged.